Definium Therapeutics is trading 4.3% up today at $45.03, continuing a strong multi-week run ahead of its next earnings report.
- The move is driven by bullish sentiment across the biotech and psychedelic drug development sectors, bolstered by recent regulatory-friendly signals.
- The price action appears to be a result of broader sector optimism rather than a new company-specific announcement or data release from the firm.